Unicycive Therapeutics Legal Actions Explained
NEW YORK — Levi & Korsinsky, LLP informs investors in Unicycive Therapeutics, Inc. about an ongoing class action securities lawsuit. If you've invested in Unicycive, it’s crucial to stay informed about these developments.
Understanding the Lawsuit
The class action seeks to recover losses for investors of Unicycive Therapeutics, Inc. who were potentially impacted by alleged securities fraud from March 29, 2024, to June 27, 2025. This timeframe is key as it defines the window during which the specific claims are being examined.
Key Allegations Against Unicycive
The lawsuit outlines serious accusations against Unicycive, suggesting that the company misrepresented its readiness for complying with FDA manufacturing requirements. This raised concerns about the regulatory prospects of their new drug application, leading to significant investor losses.
Filing a Claim
Unicycive investors who believe they have experienced a loss during this period have until October 14, 2025, to request appointment as lead plaintiffs in the case. Being a lead plaintiff is not a prerequisite for recovery, and all affected investors are encouraged to explore their options.
No Financial Risk
It’s important to know that if you are a member of the class affected, you could be entitled to compensation without incurring any out-of-pocket costs. This means there is no financial obligation to participate in the lawsuit.
Why Choose Levi & Korsinsky?
With two decades of experience, Levi & Korsinsky has garnered a strong reputation for securing compensation for shareholders affected by corporate misconduct. Our firm has built a robust track record in handling complex securities litigation, employing over 70 dedicated professionals to support clients through these challenging times.
Get In Touch
If you are looking for more information, you can reach out to Joseph E. Levi, Esq. by email or phone at (212) 363-7500. We're here to guide you through the process and ensure your rights are protected.
Frequently Asked Questions
What is the deadline for claiming damages against Unicycive?
The deadline to request to be appointed as lead plaintiff in the Unicycive case is October 14, 2025.
Are there any costs involved in participating in this lawsuit?
No, class member participants typically do not incur costs or fees to join the lawsuit.
What are the key allegations in the Unicycive lawsuit?
The allegations primarily revolve around false statements made about the company’s regulatory compliance and drug application readiness.
Who can participate in the lawsuit?
Any investors in Unicycive who suffered losses during the specified timeframe can participate in the class action.
How can I contact Levi & Korsinsky for legal help?
You can contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or by telephone at (212) 363-7500 for assistance.
